Company:  ZEALAND PHARMA A/S (ZEAL)
Form Type:  6-K
Filing Date:  10/12/2017 
CIK:  0001674988 
Address:  SMEDELAND 36
2600 GLOSTRUP
 
City, State, Zip:  COPENHAGEN,  00000 
Telephone:  (458) 877-3600 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$14.45  
Change: 
0.03 (0.21%)  
Trade Time: 
11:33 AM EST  
Market Cap: 
$444.32M
Trade ZEAL now with 

© 2017  
Description of Business
We are a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines. Our portfolio includes two approved products for the treatment of type 2 diabetes: (i) lixisenatide, which has been approved by the U.S. Food and Drug Administration, or FDA, and is marketed in the United States under the brand name Adlyxin and which has been approved by the European Medicines Agency, or EMA, and by other regulatory authorities outside the United States where it is marketed under the brand name Lyxumia, and (ii) a combination of lixisenatide with Lantus, the brand name of insulin glargine developed by Sanofi S.A., or Sanofi, which has been approved by the FDA and is marketed in the United States under the brand name Soliqua100/33, and has been approved by the EMA and launched in the Netherlands under the brand name Suliqua. Suliqua is expected to be launched in certain other European countries beginning in the second half of 2017.
Register and access this filing in:     
  FORM 6-K
    SIGNATURE
  EXHIBIT 99.1